Q2 2026 Aquestive Therapeutics Inc Earnings Call Transcript
Key Points
- Aquestive Therapeutics Inc (AQST) is on track to resubmit its Anaphylm NDA in Q3 2026, less than eight months after receiving a CRL, with improved human factors study results showing a major reduction in packaging difficulties and administration errors.
- The latest PK study showed no statistical difference between clinician-administered and self-administered Anaphylm, and even in a misadministration scenario, pharmacodynamic responses compared favorably to manual IM administration.
- The company believes the epinephrine rescue market opportunity exceeds $1 billion annually, with potential to reach $2 billion, driven by consistent market growth of around 6% per year.
- Aquestive Therapeutics Inc (AQST) completed a refinancing with Oaktree, establishing a new $150 million debt facility that lowers cost of capital and extends the interest-only period, enhancing financial flexibility.
- Total revenues increased 38% year-over-year in Q2 2026, driven by higher manufacture and supply revenue and license and royalty revenue, with non-GAAP adjusted EBITDA loss improving to $5.2 million from $9.3 million in the prior year quarter.
- Aquestive Therapeutics Inc (AQST) faces uncertainty regarding the FDA review timeline for the Anaphylm resubmission, with the base case being a six-month review, which could delay potential launch.
- The company recorded a one-time loss on extinguishment of debt of $11.7 million in Q2 2026, contributing to a net loss of $22.9 million for the quarter.
- SG&A expenses increased in Q2 2026 due to higher legal fees, severance costs, and personnel costs, partially offset by lower commercial spending.
- The company's cash position of $98.5 million may be insufficient to support a launch without additional funding, relying on $75 million from RTW and $20 million from Oaktree post-approval, which are subject to conditions.
- Aquestive Therapeutics Inc (AQST) continues to face competition in the epinephrine market, and the need to convert patients from auto-injectors to Anaphylm may be challenging, as patients tend to refill rather than switch prescriptions.
Ladies and gentlemen, thank you for standing by. Welcome to the second quarter Aquestive Therapeutics earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would like now to turn the conference over to Faith Pomeroy-Ward, Investor Relations. Please go ahead.
Thank you, operator. Good morning and welcome to today's call.
On today's call, I am joined by Dan Barber, President and Chief Executive Officer, and Ernie Toth, Chief Financial Officer, who are going to provide an overview of the company's reported financial results for the second quarter ended June 30, 2026, and a progress update on the company's key 2026 objectives, followed by a Q&A session.
During the Q&A session, the team will be joined by Dr. Matt Greenhawt, Chief Medical Officer; Melina Cioffi, Senior Vice President, Regulatory Affairs; Sherry Korczynski, Chief Commercial Officer; and Dr. Matthew Davis, Chief Development
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
